Trial reportAnnals of surgery2015
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).
Trial report in Annals of surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07643584 (DEMAND - A Phase II Trial of De-Escalation of Axillary Management in Advanced Nodal Disease), which is not on this map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DEMAND - A Phase II Trial of De-Escalation of Axillary Management in Advanced Nodal Disease
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2026Pooled it
- Pooled it
- Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.Oncotarget · 2017Trial
- Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.Breast cancer research and treatment · 2017Trial
- Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysis.NPJ breast cancer · 2026Article
- Article
- MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study.Frontiers in oncology · 2026Article
- Deep Learning Radiomics of Multiparametric MRI for Individualized Prediction of Axillary Lymph Node Response After Neoadjuvant Chemotherapy in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Axillary management in the post-neoadjuvant setting: dual tracer vs. single tracer for sentinel lymph node biopsy.Updates in surgery · 2025Article
- [Modern surgical treatment of breast cancer. 5th Breast Cancer Consensus Conference].Magyar onkologia · 2025Article
- Prediction of axillary lymph node metastasis in T1 breast cancer using diffuse optical tomography, strain elastography and molecular markers.Quantitative imaging in medicine and surgery · 2025Article
- Higher Rates of Visualization for Axillary Reverse Mapping Using Indocyanine Green Fluorescence Compared With Blue Dye.The Journal of surgical research · 2025Article
- Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer.Journal of Cancer · 2025Article
- De-escalation of axillary interventions in the management of breast cancer patients following neoadjuvant systemic treatment.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Accuracy and Influencing Factors of Axillary Lymph Node Ultrasound Assessment After Neoadjuvant Chemotherapy in Breast Cancer.Breast cancer (Dove Medical Press) · 2025Article
- Habitat imaging with intratumoral radiomics for prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients.Frontiers in molecular biosciences · 2025Article
- A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.British journal of cancer · 2024Article
- Axillary surgical staging after neoadjuvant chemotherapy: does technical accuracy matter?Gland surgery · 2024Article
- Two step procedures: sequels are never any good.Gland surgery · 2024Article
- Clinicopathological factors associated with sentinel lymph node detection in non-small-cell lung cancer.Journal of cardiothoracic surgery · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate factors affecting sentinel lymph node (SLN) identification after neoadjuvant chemotherapy (NAC) in patients with initial node-positive breast cancer.
backgroundSLN surgery is increasingly used for nodal staging after NAC and optimal technique for SLN identification is important.
methodsThe American College of Surgeons Oncology Group Z1071 prospective trial enrolled clinical T0-4, N1-2, M0 breast cancer patients. After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned. Multivariate logistic regression modeling assessing factors influencing SLN identification was performed.
resultsOf 756 patients enrolled, 34 women withdrew, 21 were ineligible, 12 underwent ALND only, and 689 had SLN surgery attempted. At least 1 SLN was identified in 639 patients (92.7%: 95% CI: 90.5%-94.6%). Among factors evaluated, mapping technique was the only factor found to impact SLN identification; with use of blue dye alone increasing the likelihood of failure to identify the SLN relative to using radiolabeled colloid +/- blue dye (P = 0.006; OR = 3.82; 95% CI: 1.47-9.92). The SLN identification rate was 78.6% with blue dye alone; 91.4% with radiolabeled colloid and 93.8% with dual mapping agents. Patient factors (age, body mass index), tumor factors (clinical T or N stage), pathologic nodal response to chemotherapy, site of tracer injection, and length of chemotherapy treatment did not significantly affect the SLN identification rate.
conclusionsThe SLN identification rate after NAC was higher when mapping was performed using radiolabeled colloid alone or with blue dye compared with blue dye alone. Optimal tracer use is important to ensure successful identification of SLN(s) after NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.